Abstract

Breast cancer (BC) is the leading cause of cancer-related death in women. Therefore, a better understanding of BC biology and signaling pathways might lead to the development of novel biomarkers and targeted therapies. Although a number of transcriptomic studies have been performed on breast cancer patients from various geographic regions, there are almost no such comprehensive studies performed on breast cancer from patients in the gulf region. This study aimed to provide a better understanding of the altered molecular networks in BC from the gulf region. Herein, we compared the transcriptome of BC to adjacent normal tissue from six BC patients and identified 1,108 upregulated and 518 downregulated transcripts. A selected number of genes from the RNA-Seq analysis were subsequently validated using qRT-PCR. Differentially expressed (2.0-fold change, adj. p < 0.05) transcripts were subjected to ingenuity pathway analysis, which revealed a myriad of affected signaling pathways and functional categories. Activation of ERBB2, FOXM1, ESR1, and IGFBP2 mechanistic networks was most prominent in BC tissue. Additionally, BC tissue exhibited marked enrichment in genes promoting cellular proliferation, migration, survival, and DNA replication and repair. The presence of genes indicative of immune cell infiltration and activation was also observed in BC tissue. We observed high concordance [43.5% (upregulated) and 62.1% (downregulated)] between differentially expressed genes in our study group and those reported for the TCGA BC cohort. Our data provide novel insight on BC biology and suggest common altered molecular networks in BC in this geographic region. Our data suggest future development of therapeutic interventions targeting those common signaling pathways.

Highlights

  • Breast cancer (BC) is the second most common type of cancer around the world comprising approximately 11.6% of new cancer cases and 6.6% of all cancer-related deaths up to 2018 [1]

  • Gene expression profiling by DNA microarray have identified the inherent classification of BC into five main molecular subtypes: Luminal A (estrogen receptor (ER) +/progesterone receptors (PR) +/epidermal growth factor receptor 2 (HER2; ERBB2) –) are commonly of low score; luminal B (ER+/PR–/+/HER2+/–) are normally of higher score with more proliferation rate; HER2-enriched subtype (ER–/PR–/HER2+); triple-negative breast cancer (TNBC; ER–/PR–/HER2–); and carcinomas that are analogous to normal breast tissue and is associated with good prognosis [2,3,4]

  • To characterize the transcriptional landscape alterations during malignant transformation, tumor, and adjacent normal breast tissues from six BC patients were subjected to whole transcriptome RNA-Seq analysis

Read more

Summary

Introduction

Breast cancer (BC) is the second most common type of cancer around the world comprising approximately 11.6% of new cancer cases and 6.6% of all cancer-related deaths up to 2018 [1]. Gene expression profiling by DNA microarray have identified the inherent classification of BC into five main molecular subtypes: Luminal A (estrogen receptor (ER) +/progesterone receptors (PR) +/epidermal growth factor receptor 2 (HER2; ERBB2) –) are commonly of low score; luminal B (ER+/PR–/+/HER2+/–) are normally of higher score with more proliferation rate; HER2-enriched subtype (ER–/PR–/HER2+); triple-negative breast cancer (TNBC; ER–/PR–/HER2–); and carcinomas that are analogous to normal breast tissue and is associated with good prognosis [2,3,4]. Genomewide association studies have identified many novel breast cancer vulnerability variants such as hereditary risk factors, encompassing four sporadic high-penetrance transcriptomes (BRCA1, BRCA2, TP53, and PTEN), four sporadic moderate: penetrance transcriptomes (CHEK2, ATM, BRIP1, and PALB2), and around twenty common low-penetrance variants in 19 genes or loci [6, 7]

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.